Management of Biological Therapy Before Elective Inflammatory Bowel Disease Surgeries.

Management of Biological Therapy Before Elective Inflammatory Bowel Disease Surgeries. Inflamm Bowel Dis. 2019 Feb 22;: Authors: Hansen TM, Targownik LE, Karimuddin A, Leung Y Abstract Increasing uptake of biologic therapy has contributed to declining surgical rates for inflammatory bowel disease (IBD). However, a significant number of patients on biologic therapy will go on to require surgery. The literature is conflicted with regard to the preoperative management of biologic therapy before urgent or elective IBD surgery. This article reviews the available data on postoperative complications following preoperative treatment with anti-tumor…

Read More

The Influence of Preoperative Medications on Postoperative Complications in Patients After Intestinal Surgery for Crohn’s Disease.

The Influence of Preoperative Medications on Postoperative Complications in Patients After Intestinal Surgery for Crohn’s Disease. Inflamm Bowel Dis. 2019 Feb 08;: Authors: Yu CS, Jung SW, Lee JL, Lim SB, Park IJ, Yoon YS, Kim CW, Ynag SK, Ye BD, Park SH, Han M, Kim JC Abstract Background: Many patients with Crohn’s disease (CD) are treated with medications, including steroids, immunomodulators, and anti-tumor necrosis factor alpha (anti-TNF-α) agents, at the time of surgery. This study evaluated the effects of these medications on postoperative complications in CD patients. Methods: This…

Read More

Early Postoperative Anti-TNF Therapy Does Not Increase Complications Following Abdominal Surgery in Crohn’s Disease.

Related Articles Early Postoperative Anti-TNF Therapy Does Not Increase Complications Following Abdominal Surgery in Crohn’s Disease. Dig Dis Sci. 2019 Jan 25;: Authors: Schad CA, Haac BE, Cross RK, Syed A, Lonsako S, Bafford AC Abstract BACKGROUND: The impact of postoperative anti-TNF therapy on infectious complications following Crohn’s disease surgery remains controversial. Use of anti-TNF therapy 2-4 weeks postoperatively appears safe, but safety of use within 2 weeks is unknown. AIMS: We sought to evaluate the effect of anti-TNF therapy initiated within 2 weeks of abdominal surgery in patients with Crohn’s disease. METHODS:…

Read More

Increased prevalence of anti-TNF therapy in paediatric inflammatory bowel disease is associated with a decline in surgical resections during childhood.

Related Articles Increased prevalence of anti-TNF therapy in paediatric inflammatory bowel disease is associated with a decline in surgical resections during childhood. Aliment Pharmacol Ther. 2019 Jan 09;: Authors: Ashton JJ, Borca F, Mossotto E, Coelho T, Batra A, Afzal NA, Phan HTT, Stanton M, Ennis S, Beattie RM Abstract BACKGROUND: Anti-tumour necrosis factor-α (anti-TNF) therapy use has risen in paediatric-onset inflammatory bowel disease (PIBD). Whether this has translated into preventing/delaying childhood surgery is uncertain. The Wessex PIBD cohort was analysed for trends in anti-TNF-therapy and surgery. DESIGN: All patients…

Read More

Decreasing Risk of First and Subsequent Surgeries in Patients With Crohn’s Disease in England From 1994 through 2013.

Related Articles Decreasing Risk of First and Subsequent Surgeries in Patients With Crohn’s Disease in England From 1994 through 2013. Clin Gastroenterol Hepatol. 2018 Dec 21;: Authors: Burr NE, Lord R, Hull MA, Subramanian V Abstract BACKGROUND & AIMS: Gastrointestinal (GI) surgery is an important part of the treatment algorithm for patients with Crohn’s disease (CD) that is complicated or does not respond to medical therapy. Cohort studies from Denmark and Canada have shown that the risk of primary surgery is decreasing but there is a lack of contemporary data…

Read More

Editorial: predicting recurrence of Crohn’s disease after surgical resection-Close to a crystal ball. Authors’ reply.

Editorial: predicting recurrence of Crohn’s disease after surgical resection-Close to a crystal ball. Authors’ reply. Aliment Pharmacol Ther. 2018 Nov;48(10):1157-1158 Authors: Allez M, Auzolle C, Le Bourhis L, Seksik P PMID: 30375683 [PubMed – in process] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/30375683?dopt=Abstract

Read More

Smoking Status at Diagnosis and Subsequent Smoking Cessation: Associations With Corticosteroid Use and Intestinal Resection in Crohn’s Disease.

Related Articles Smoking Status at Diagnosis and Subsequent Smoking Cessation: Associations With Corticosteroid Use and Intestinal Resection in Crohn’s Disease. Am J Gastroenterol. 2018 Oct 15;: Authors: Alexakis C, Saxena S, Chhaya V, Cecil E, Majeed A, Pollok R Abstract BACKGROUND: The impact of smoking at diagnosis and subsequent smoking cessation on clinical outcomes in Crohn’s disease (CD) has not been evaluated in a population-based cohort. METHODS: Using a nationally representative clinical research database, we identified incident cases of CD between 2005 and 2014. We compared the following outcomes: overall…

Read More

Creeping Fat Assessed by Small Bowel MRI Is Linked to Bowel Damage and Abdominal Surgery in Crohn’s Disease.

Related Articles Creeping Fat Assessed by Small Bowel MRI Is Linked to Bowel Damage and Abdominal Surgery in Crohn’s Disease. Dig Dis Sci. 2018 Oct 01;: Authors: Althoff P, Schmiegel W, Lang G, Nicolas V, Brechmann T Abstract BACKGROUND: Crohn’s disease (CD) leads to bowel damage and surgery in a significant proportion of patients. AIMS: The aim of the study was to evaluate the predictive value of creeping fat assessed by small bowel MRI in CD patients. METHODS: CD patients undergoing small bowel MRI were included in a retrospective observational…

Read More

Colon Surgery Risk With Corticosteroids Versus Immunomodulators or Biologics in Inflammatory Bowel Disease Patients With Clostridium difficile Infection.

Colon Surgery Risk With Corticosteroids Versus Immunomodulators or Biologics in Inflammatory Bowel Disease Patients With Clostridium difficile Infection. Inflamm Bowel Dis. 2018 Sep 26;: Authors: Solanky D, Pardi DS, Loftus EV, Khanna S Abstract Background: Inflammatory bowel disease (IBD) is an independent risk factor for Clostridium difficile infection (CDI), and CDI often precipitates IBD exacerbation. Because CDI cannot be distinguished clinically from an IBD exacerbation, management is difficult. We aimed to assess factors associated with adverse outcomes in IBD with CDI, including the role of escalating or de-escalating IBD therapy…

Read More
<< Go Back